Annual Report 2020

Division of Molecular Pathology

Yasushi Yatabe, Nobuyoshi Hiraoka, Shigeki Sekine, Taisuke Mori, Yoshihisa Kobayashi, Takashi Teishikata, Taiki Hashimoto, Jumpei Kashima, Yuuki Nishimura, Yu Ohkubo, Keiko Ishiyama, Reiko Ogawa, Chie Naito, Masanori Fuse, Eijitu Ryo, Keiichiro Iwase, Sachiyo Hasegawa, Nozomi Handa

 Introduction

 Morphological analysis is one of the oldest fields in cancer research; thus this field covers a wide range of knowledge that has been developing for several decades. The division of molecular pathology aims to integrate this knowledge with the rapidly evolving field of molecular biology to study the molecular biological characteristics of tumors from the morphological perspective.

 The Team and What We Do

 Diagnoses are now made on the basis of various protein expressions and genetic abnormalities that go beyond morphology, and drugs that are highly effective against specific genetic mutations have been developed for some tumors. In the field of molecular pathology, we collaborate closely with the Department of Diagnostic Pathology of Central Hospital and conduct research on the use of genetic alterations that are useful in the diagnosis and identification of genetic abnormalities, based on the questions raised in the diagnostic process. We are also investigating the molecular mechanisms of tumorigenesis and progression based on the results of various biologic research studies and cancer genome medicine.

 Research activities

 Lung Cancer: As one of the studies to elucidate the carcinogenic mechanism of lung cancer linked to clinical findings, we reported that the poor response of non-small cell lung cancer with EGFR and ALK alterations to immune checkpoint inhibitors could be explained by differences in the underlying mechanism of molecular carcinogenesis.

 Gastrointestinal cancer: We have focused on the serrated pathway, which is a carcinogenic pathway different from the adenoma-carcinoma sequence in colorectal cancer. In addition, we have recently reported on the serrated lesions in familial colorectal adenomatosis, including a new serrated lesion, superficially serrated adenoma, which we proposed, and the carcinogenic process mediated by serrated adenoma.

 Head and Neck Cancer: TP53 mutational status of 126 pairs of initial and recurrent head and neck squamous cell carcinoma tumor cases was analyzed. About one-third of the recurrent cases showed different TP53 status from the initial tumors. Survival after recurrence was related to the TP53 status of the recurrent tumor, which was useful for the prognosis.

 Pancreatic Cancer: In pancreatic cancer tissues, dysfunctional vascular endothelial cells that do not sufficiently support lymphocyte extravasation are one of the factors that lead to decreased antitumor immunity. We found that this dysfunction was associated with an abnormality in the TNFR1 signaling pathway, identified a small molecule compound that restores this dysfunction, and reported that the administration of the compound enhances the antitumor immune response to the tumor.

 Trans-organ approach: We have established an experimental system to create fusion genes by applying CRISPR-Cas9, which cuts the DNA of target genes. Using this technique, they showed that TMEM87A-RASGRF1, found in patients who responded to a phase II trial of the multi-kinase inhibitor sunitinib, activates the MAPK pathway and becomes oncogenic.

 Education

 We accepted three graduated fellows and trained them in cancer research.

 Future Prospects

 With advances in basic research and the spread of cancer genome medicine, fundamental genetic disorders have been discussed in clinical settings. The aim of our research is to use our morphological approach as a means of assigning biological meaning/significance to individual disease and obtaining background molecular features across the organs.

List of papers published in 2020

Journal

1. Kobayashi K, Yoshimoto S, Ando M, Matsumoto F, Murakami N, Omura G, Honma Y, Matsumoto Y, Ikeda A, Sakai A, Eguchi K, Ito A, Ryo E, Yatabe Y, Mori T. Full-coverage TP53 deep sequencing of recurrent head and neck squamous cell carcinoma facilitates prognostic assessment after recurrence. Oral Oncol, 113:105091, 2021

2. Yoshida H, Nishikawa T, Matsumoto K, Mori M, Hirashima Y, Takehara K, Ariyoshi K, Hasegawa K, Yonemori K. Histopathological features of HER2 overexpression in uterine carcinosarcoma: proposal for requirements in HER2 testing for targeted therapy. Virchows Arch, 478:1161-1171, 2021

3. Shibayama T, Makise N, Motoi T, Mori T, Hiraoka N, Yonemori K, Watanabe SI, Esaki M, Morizane C, Okuma T, Kawai A, Ushiku T, Yatabe Y, Yoshida A. Clinicopathologic Characterization of Epithelioid Hemangioendothelioma in a Series of 62 Cases: A Proposal of Risk Stratification and Identification of a Synaptophysin-positive Aggressive Subset. Am J Surg Pathol, 45:616-626, 2021

4. Cho H, Yamada M, Sekine S, Tanabe N, Ushiama M, Hirata M, Ogawa G, Gotoh M, Yoshida T, Yoshikawa T, Saito Y, Kuchiba A, Oda I, Sugano K. Gastric cancer is highly prevalent in L ynch syndrome patients with atrophic gastritis. Gastric Cancer, 24:283-291, 2021

5. Tsutsui K, Namikawa K, Mori T, Kato K, Jinnai S, Nakama K, Ogata D, Takahashi A, Yamazaki N. Case of acquired reactive perforating collagenosis induced by panitumumab for colon cancer. J Dermatol, 48:e114-e115, 2021

6 Muto Y, Ryo E, Namikawa K, Takahashi A, Ogata D, Fujimura T, Yatabe Y, Aiba S, Yamazaki N, Mori T. RB1 gene mutations are a distinct predictive factor in Merkel cell carcinoma. Pathol Int, 71:337- 347, 2021

7. Takamizawa S, Honma Y, Murakami N, Mori T, Oka H, Yamamoto S, Kashihara T, Ito K, Kubo Y, Ikeda A, Matsumoto F, Omura G, Kobayashi K, Itami J, Kato K, Yoshimoto S. Short-term outcomes of induction chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF) in locally advanced nasopharyngeal carcinoma. Invest New Drugs, 39:564-570, 2021

8. Murakami N, Mori T, Machida R, Kodaira T, Ito Y, Shikama N, Konishi K, Matsumoto Y, Murakami Y, Nakamura N, Yamashita H, Yorozu A, Yoshimura M, Inoue K, Nozaki M, Ishikura S, Itami J, Nishimura Y, Kagami Y. Prognostic Value of Epithelial Cell Adhesion Molecules in T1-2N0M0 Glottic Cancer. Laryngoscope, 131:1522-1527, 2021

9. Karigane D, Kasahara H, Shiroshita K, Fujita S, Kobayashi H, Tamaki S, Yamazaki R, Yahagi K, Yatabe Y, Kondoh N, Arai T, Katagiri H, Shimizu N, Sakurai M, Kikuchi T, Kato J, Shimizu T, Hayakawa T, Yaguchi T, Matsushita M, Nakaj ima H, Kawakami Y, Murata M, Mori T, Sasaki T, Okamoto S, Takubo K. Detection of residual disease in chronic myeloid leukemia utilizing genomic next generation sequencing reveals persistence of dif ferentiated Ph+ B cells but not bone marrow stem/progenitors. Leuk Lymphoma, 62:679-687, 2021

10. Meng X, Matsumoto F, Mori T, Miura N, Ino Y, Onidani K, Kobayashi K, Matsuzaki Y, Yoshimoto S, Ikeda K, Honda K. BP180 Is a Prognostic Factor in Head and Neck Squamous Cell Carcinoma. Anticancer Res, 41:1089-1099, 2021

11. Mino-Kenudson M, Le Stang N, Daigneault JB, Nicholson AG, Cooper WA, Roden AC, Moreira AL, Thunnissen E, Papotti M, Pelosi G, Motoi N, Poleri C, Brambilla E, Redman M, Jain D, Dacic S, Yatabe Y, Tsao MS, Lopez-Rios F, Botling J, Chen G, Chou TY, Hirsch FR, Beasley MB, Borczuk A, Bubendorf L, Chung JH, Hwang D, Lin D, Longshore J, Noguchi M, Rekhtman N, Sholl L, Travis W, Yoshida A, Wynes MW, Wistuba II, Kerr KM, Lantuejoul S. The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC. J Thorac Oncol, 16:686-696, 2021

12. Naruse M, Ochiai M, Sekine S, Taniguchi H, Yoshida T, Ichikawa H, Sakamoto H, Kubo T, Matsumoto K, Ochiai A, Imai T. Re-expression of REG family and DUOXs genes in CRC organoids by co-culturing with CAFs. Sci Rep, 11:2077, 2021   

13. Ota Y, Noguchi T, Ariji E, Fushimi C, Fuwa N, Harada H, Hayashi T, Hayashi R, Honma Y, Miura M, Mori T, Nagatsuka H, Okura M, Ueda M, Uzawa N, Yagihara K, Yagishita H, Yamashiro M, Yanamoto S, Kirita T. General rules for clinical and pathological studies on oral cancer (2nd edition): a synopsis. Int J Clin Oncol, 26:623-635, 2021

14. Sakao Y, Kuroda H, Saito Y, Yamauchi Y, Yokote F, Kawamura M, Yatabe Y. Radiological imaging and pathological findings of small lung adenocarcinoma: a narrative review. J Thorac Dis, 13:366-371, 2021

15. Takeyasu Y, Yoshida T, Motoi N, Teishikata T, Tanaka M, Matsumoto Y, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Kakishima H, Tsuchida T, Yamamoto N, Ohe Y, Yatabe Y. Feasibility of nextgeneration sequencing (Oncomine DX Target Test) for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients. Jpn J Clin Oncol, 2021

16. Ueda S, Yamashita S, Watanabe SI, Wakabayashi M, Motoi N, Noguchi M, Sekine S, Sato Y, Ushijima T. Influence of degree of DNA degradation in formalin-fixed and paraf fin-embedded tissue samples on accuracy of genome-wide DNA methylation analysis. Epigenomics, 13:565-576, 2021

17. Yagishita S, Kato K, Takahashi M, Imai T, Yatabe Y, Kuwata T, Suzuki M, Ochiai A, Ohtsu A, Shimada K, Nishida T, Hamada A, Mano H. Characterization of the large-scale Japanese patient-derived xenograft (J-PDX) library. Cancer Sci, 112:2454- 2466, 2021

18. Yasukawa Y, Hattori N, Iida N, Takeshima H, Maeda M, Kiyono T, Sekine S, Seto Y, Ushijima T. SAA1 is upregulated in gastric cancer-associated fibroblasts possibly by its enhancer activation. Carcinogenesis, 42:180-189, 2021

19. Yatabe Y, Yoshiki Y, Matsumura K, Togo K, Kikkawa H, Iadeluca L, Li B, Nishio K. Real-World Evidence of Diagnostic Testing for Driver Oncogene Mutations in Lung Cancer in Japan. JTO Clinical and Research Reports, 2:100136, 2021 20. Yonemaru J, Hashimoto T, Takayanagi D, Naka T, Yatabe Y, Kanemitsu Y, Shiraishi K, Sekine S. NTRK fusion-positive colorectal cancer in Japanese population. Pathol Int, 71:355-359, 2021

20. Yorozu T, Nagahama K, Morii T, Maeda D, Yoshida A, Mori T, Hayashi A, Shibahara J. Myoepitheliomalike Hyalinizing Epithelioid Tumor of the Foot Harboring an OGT-FOXO1 Fusion. Am J Surg Pathol, 45:287-290, 2021

21. Yoshida A, Hashimoto T, Ryo E, Yoshida KI, Motoi T, Yatabe Y, Mori T. Confirmation of NKX3-1 Expression in EWSR1-NFATC2 Sarcoma and Mesenchymal Chondrosarcoma Using Monoclonal Antibody Immunohistochemistry, RT-PCR, and RNA In Situ Hybridization. Am J Surg Pathol, 45:578-582, 2021

22. Matsuzuka T, Uemura H, Yoshimoto S, Miura K, Shiotani A, Sugasawa M, Homma A, Yokoyama J, Tsukahara K, Yoshizaki T, Yatabe Y, Kobari T, Kosuda S, Murono S, Hasegawa Y. Attempting to define sentinel node micrometastasis in oral squamous cell carcinoma. Fukushima J Med Sci, 66:143-147, 2020

23. Makise N, Mori T, Kobayashi H, Nakagawa K, Ryo E, Nakajima J, Kohsaka S, Mano H, Aburatani H, Yoshida A, Ushiku T. Mesenchymal tumours with RREB1-MRTFB fusion involving the mediastinum: extra-glossal ectomesenchymal chondromyxoid tumours? Histopathology, 76:1023-1031, 2020

24. Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L, Bunn P, Cascone T, Chaft J, Chen G, Chou TY, Cooper W, Erasmus JJ, Ferreira CG, Goo JM, Heymach J, Hirsch FR, Horinouchi H, Kerr K, Kris M, Jain D, Kim YT, Lopez-Rios F, Lu S, Mitsudomi T, Moreira A, Motoi N, Nicholson AG, Oliveira R, Papotti M, Pastorino U, Paz-Ares L, Pelosi G, Poleri C, Provencio M, Roden AC, Scagliotti G, Swisher SG, Thunnissen E, Tsao MS, Vansteenkiste J, Weder W, Yatabe Y. IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. J Thorac Oncol, 15:709- 740, 2020

25. Kanamori K, Yamagata Y, Honma Y, Date K, Wada T, Hayashi T, Otsuki S, Sekine S, Yoshikawa T, Katai H, Nishida T. Extra-gastrointestinal stromal tumor arising in the lesser omentum with a plateletderived growth factor receptor alpha (PDGFRA) mutation: a case report and literature review. World J Surg Oncol, 18:183, 2020 66. Tamura N, Honma Y, Sekine S, Tsukamoto S, Hirano H, Okita N, Shoji H, Iwasa S, Takashima A, Kato K, Boku N. Case report: potential treatment of metastatic amphicrine carcinoma of the rectum with FOLFOXIRI chemotherapy. Oxf Med Case Reports, 2020:omaa097, 2020

26. Sekine S, Yamashita S, Yamada M, Hashimoto T, Ogawa R, Yoshida H, Taniguchi H, Kojima M, Ushijima T, Saito Y. Clinicopathological and molecular correlations in traditional serrated adenoma. J Gastroenterol, 55:418-427, 2020

27. Okamura T, Hashimoto T, Naka T, Yoshida T, Tanabe N, Ogawa R, Yamada M, Saito Y, Yatabe Y, Sekine S. Clinicopathologic and Molecular Characteristics of Familial Adenomatous Polyposisassociated Traditional Serrated Adenoma. Am J Surg Pathol, 44:1282-1289, 2020

28. Okamura T, Hashimoto T, Naka T, Yoshida T, Tanabe N, Ogawa R, Yamada M, Saito Y, Yatabe Y, Sekine S. Clinicopathologic and Molecular Characteristics of Familial Adenomatous Polyposisassociated Traditional Serrated Adenoma. Am J Surg Pathol, 44:1282-1289, 2020

29. Nonaka S, Hashimoto T, Oda I, Sekine S. Sporadic pyloric gland adenoma associated with a large fundic gland polyp: genetic evidence for stepwise progression. Gastric Cancer, 23:1102-1106, 2020

30. Watanabe H, Yamazaki Y, Fujishima F, Izumi K, Imamura M, Hijioka S, Toriyama K, Yatabe Y, Kudo A, Motoi F, Unno M, Sasano H. O(6)- methylguanine DNA methyltransferase and glucose transporter 2 in foregut and hindgut gastrointestinal neuroendocrine neoplasms. BMC Cancer, 20:1195, 2020

31. Mizuta H, Takahashi A, Mori T, Namikawa K, Nakano E, Muto Y, Jinnai S, Nakama K, Tsutsui K, Yamazaki N. Ef ficacy of oral retinoids for keratoacanthoma centrifugum marginatum. Dermatol Ther, 33:e13291, 2020

32. Tsutsui K, Namikawa K, Mori T, Jinnai S, Nakama K, Ogata D, Takahashi A, Yamazaki N. Case of multiple ectopic extramammary Paget's disease of the trunk. J Dermatol, 47:e329-e331, 2020

33. Chatani S, Hasegawa T, Kato S, Murata S, Sato Y, Yamaura H, Yamamoto K, Yatabe Y, Inaba Y. Imageguided core needle biopsy in the diagnosis of malignant lymphoma: comparison with surgical excision biopsy. Eur J Radiol, 127:108990, 2020

34. Edwards JG, Chansky K, Van Schil P, Nicholson AG, Boubia S, Brambilla E, Donington J, Galateau- Sall? F, Hoffmann H, Infante M, Marino M, Marom EM, Nakajima J, Ostrowski M, Travis WD, Tsao MS, Yatabe Y, Giroux DJ, Shemanski L, Crowley J, Krasnik M, Asamura H, Rami-Porta R. The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non-Small Cell Lung Cancer. J Thorac Oncol, 15:344-359, 2020

35. Fujiyoshi T, Tajika M, Tanaka T, Ishihara M, Mizuno N, Hara K, Hijioka S, Imaoka H, Yatabe Y, Hirooka Y, Goto H, Yamao K, Niwa Y. Corrigendum to: Comparative evaluation of new and conventional classifications of magnifying endoscopy with narrow band imaging for invasion depth of superficial esophageal squamous cell carcinoma. Dis Esophagus, 33:2020

36. Kawasaki K, Toshimitsu K, Matano M, Fujita M, Fujii M, Togasaki K, Ebisudani T, Shimokawa M, Takano A, Takahashi S, Ohta Y, Nanki K, Igarashi R, Ishimaru K, Ishida H, Sukawa Y, Sugimoto S, Saito Y, Maejima K, Sasagawa S, Lee H, Kim HG, Ha K, Hamamoto J, Fukunaga K, Maekawa A, Tanabe M, Ishihara S, Hamamoto Y, Yasuda H, Sekine S, Kudo A, Kitagawa Y, Kanai T, Nakagawa H, Sato T. An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-Phenotype Mapping. Cell, 183:1420-1435.e21, 2020

37. Kuwata T, Wakabayashi M, Hatanaka Y, Morii E, Oda Y, Taguchi K, Noguchi M, Ishikawa Y, Nakajima T, Sekine S, Nomura S, Okamoto W, Fujii S, Yoshino T. Impact of DNA integrity on the success rate of tissue-based next-generation sequencing: Lessons from nationwide cancer genome screening project SCRUM-Japan GISCREEN. Pathol Int, 70:932-942, 2020

38. Lantuejoul S, Sound-Tsao M, Cooper WA, Girard N, Hirsch FR, Roden AC, Lopez-Rios F, Jain D, Chou TY, Motoi N, Kerr KM, Yatabe Y, Brambilla E, Longshore J, Papotti M, Sholl LM, Thunnissen E, Rekhtman N, Borczuk A, Bubendorf L, Minami Y, Beasley MB, Botling J, Chen G, Chung JH, Dacic S, Hwang D, Lin D, Moreira A, Nicholson AG, Noguchi M, Pelosi G, Poleri C, Travis W, Yoshida A, Daigneault JB, Wistuba II, Mino-Kenudson M. PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee. J Thorac Oncol, 15:499-519, 2020

39. Matsuda K, Kashima J, Yatabe Y. The Isoform Matters in NUT Carcinoma: A Diagnostic Pitfall of p40 Immunohistochemistr y. J Thorac Oncol, 15:e176-e178, 2020

40. Matsui T, Sakakura N, Koyama S, Nakanishi K, Sasaki E, Kato S, Hosoda W, Murakami Y, Kuroda H, Yatabe Y. Comparison of Surgical Outcomes Between Invasive Mucinous and Non-Mucinous Lung Adenocarcinoma. Ann Thorac Surg, 2020 108. Moreira AL, Ocampo PSS, Xia Y, Zhong H, Russell PA, Minami Y, Cooper WA, Yoshida A, Bubendorf L, Papotti M, Pelosi G, Lopez-Rios F, Kunitoki K, Ferrari-Light D, Sholl LM, Beasley MB, Borczuk A, Botling J, Brambilla E, Chen G, Chou TY, Chung JH, Dacic S, Jain D, Hirsch FR, Hwang D, Lantuejoul S, Lin D, Longshore JW, Motoi N, Noguchi M, Poleri C, Rekhtman N, Tsao MS, Thunnissen E, Travis WD, Yatabe Y, Roden AC, Daigneault JB, Wistuba II, Kerr KM, Pass H, Nicholson AG, Mino-Kenudson M. A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol, 15:1599-1610, 2020

41. Motoi N, Yatabe Y. Lung cancer biomarker tests: the history and perspective in Japan. Transl Lung Cancer Res, 9:879-886, 2020

42. Sasaki E, Masago K, Fujita S, Hanai N, Yatabe Y. Frequent KRAS and HRAS mutations in squamous cell papillomas of the head and neck. J Pathol Clin Res, 6:154-159, 2020

43. Namikawa K, Takahashi A, Mori T, Tsutsumida A, Suzuki S, Motoi N, Jinnai S, Kage Y, Mizuta H, Muto Y, Nakano E, Yamazaki N. Nivolumab for patients with metastatic uveal melanoma previously untreated with ipilimumab: a single-institution retrospective study. Melanoma Res, 30:76-84, 2020

44. Numakura S, Saito K, Motoi N, Mori T, Saito Y, Yokote F, Kanamoto Y, Asami M, Sakai T, Yamauchi Y, Sakao Y, Uozaki H, Kawamura M. P63-negative pulmonary NUT carcinoma arising in the elderly: a case report. Diagn Pathol, 15:134, 2020

45. Satomi K, Jimbo K, Shimizu C, Sekine C, Iwamoto E, Murata T, Shiino S, Takayama S, Maeshima A, Kinoshita T, Tamura K, Yoshida M. Unusual S-100 and SOX10 immunoreactivity in a case of basal- HER2 metaplastic carcinoma of the breast: A potential diagnostic pitfall. Human Pathology: Case Reports, 21:200394, 2020

46. Seo T, Noguchi E, Yoshida M, Mori T, Tanioka M, Sudo K, Shimomura A, Yonemori K, Fujiwara Y, Tamura K. Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation. Case Rep Oncol Med, 2020:2518383, 2020

47. Seto K, Haneda M, Masago K, Fujita S, Kato S, Sasaki E, Hosoda W, Murakami Y, Kuroda H, Horio Y, Hida T, Okubo K, Yatabe Y. Negative reactions of BRAF mutation-specific immunohistochemistry to non-V600E mutations of BRAF. Pathol Int, 70:253- 261, 2020

48. Shiokawa D, Sakai H, Ohata H, Miyazaki T, Kanda Y, Sekine S, Narushima D, Hosokawa M, Kato M, Suzuki Y, Takeyama H, Kambara H, Nakagama H, Okamoto K. Slow-Cycling Cancer Stem Cells Regulate Progression and Chemoresistance in Colon Cancer. Cancer Res, 80:4451-4464, 2020

49. Sholl LM, Hirsch FR, Hwang D, Botling J, Lopez- Rios F, Bubendorf L, Mino-Kenudson M, Roden AC, Beasley MB, Borczuk A, Brambilla E, Chen G, Chou TY, Chung JH, Cooper WA, Dacic S, Lantuejoul S, Jain D, Lin D, Minami Y, Moreira A, Nicholson AG, Noguchi M, Papotti M, Pelosi G, Poleri C, Rekhtman N, Tsao MS, Thunnissen E, Travis W, Yatabe Y, Yoshida A, Daigneault JB, Zehir A, Peters S, Wistuba II, Kerr KM, Longshore JW. The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol, 15:1409-1424, 2020

50. Taniguchi H, Uehara K, Nakayama G, Nakayama H, Aiba T, Hattori N, Kataoka M, Nakano Y, Kawase Y, Okochi O, Matsuoka H, Utsunomiya S, Sakamoto E, Mori Y, Umeda S, Shikano T, Komori K, Tajika M, Kadowaki S, Muro K, Yatabe Y. Tumor Location Is Associated With the Prevalence of Braf And Pik3ca Mutations in Patients with Wild-Type Ras Colorectal Cancer: A Prospective Multi-Center Cohort Study in Japan. Transl Oncol, 13:100786, 2020

51. Tsutsui K, Takahashi A, Mori T, Namikawa K, Yamazaki N. Secretory carcinoma of the skin arising on the eyelid, distinguished by immunohistochemical markers and fluorescence in situ hybridization. J Dermatol, 47:e99-e100, 2020

52. Yatabe Y, Sunami K, Goto K, Nishio K, Aragane N, Ikeda S, Inoue A, Kinoshita I, Kimura H, Sakamoto T, Satouchi M, Shimizu J, Tsuta K, Toyooka S, Nishino K, Hatanaka Y, Matsumoto S, Mikubo M, Yokose T, Dosaka-Akita H. Multiplex gene-panel testing for lung cancer patients. Pathol Int, 70:921- 931, 2020

53. Yatabe Y. Reassessing the SCLC Subtypes. J Thorac Oncol, 15:1819-1822, 2020

54. Yokota T, Saito Y, Takamaru H, Sekine S, Nakajima T, Yamada M, Sakamoto T, Taniguchi H, Kushima R, Tsukamoto S, Shida D, Kanemitsu Y, Matsuda T. Spontaneous Regression of Mismatch Repair- Deficient Colon Cancer: A Case Series. Clin Gastroenterol Hepatol, 2020

55. Cooper AJ, Kobayashi Y, Kim D, Clifford SE, Kravets S, Dahlberg SE, Chambers ES, Li J, Rangachari D, Nguyen T, Costa DB, Rabin MS, Wagle N, Sholl LM, J?nne PA, Oxnard GR. Identification of a RAS-activating TMEM87ARASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non-Small Cell Lung Cancer. Clin Cancer Res, 26:4072-4079, 2020